[HTML][HTML] How to build and interpret a nomogram for cancer prognosis

…, D Schrag, GV Raj, KS Panageas - Journal of clinical …, 2008 - nlp.case.edu
Nomograms are widely used for cancer prognosis, primarily because of their ability to reduce
statistical predictive models into a single numerical estimate of the probability of an event, …

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

…, JR Giles, B Wenz, M Adamow, D Kuk, KS Panageas… - Nature, 2017 - nature.com
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1)
in human melanoma, most patients do not experience durable clinical benefit. Pre-existing …

[HTML][HTML] Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated …

…, SP D'Angelo, KM Woo, KS Panageas… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Ipilimumab is a standard treatment for metastatic melanoma, but immune-related
adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary …

KIT as a therapeutic target in metastatic melanoma

…, PB Chapman, RA Roman, J Teitcher, KS Panageas… - Jama, 2011 - jamanetwork.com
Context Some melanomas arising from acral, mucosal, and chronically sun-damaged sites
harbor activating mutations and amplification of the type III transmembrane receptor tyrosine …

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

…, S Saxman, AN Destro, KS Panageas… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen
(dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in …

Developing a cancer‐specific geriatric assessment: A feasibility study

…, H Muss, M Rodin, KS Panageas… - … Journal of the …, 2005 - Wiley Online Library
BACKGROUND As the US population ages, there is an emerging need to characterize the “functional
age” of older patients with cancer to tailor treatment decisions and stratify …

[HTML][HTML] Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification

…, L Tan, S Kaptain, A Bach, KS Panageas… - Journal of Clinical …, 2001 - nlp.case.edu
PURPOSE: This phase II study evaluated weekly trastuzumab and paclitaxel therapy in
women with HER2-normal and HER2-overexpressing metastatic breast cancer. Efficacy was …

[PDF][PDF] Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model

LE Abrey, L Ben-Porat, KS Panageas… - Journal of Clinical …, 2006 - researchgate.net
… Primary CNS lymphoma (PCNSL) is a rare variant of non-Hodgkin’s lymphoma that involves
the brain, leptomeninges, eyes, or spinal cord. Over the last 20 years, the treatment of PCNSL …

Risk of arterial thromboembolism in patients with cancer

…, PM Okin, MSV Elkind, KS Panageas… - Journal of the American …, 2017 - jacc.org
Background : The risk of arterial thromboembolism in patients with cancer is incompletely
understood. Objectives : The authors aimed to better define this epidemiological relationship, …

Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with …

…, SEA Schroeder, KS Panageas… - … Journal of the …, 2010 - Wiley Online Library
BACKGROUND: Ipilimumab is a monoclonal antibody that antagonizes cytotoxic T lymphocyte
antigen‐4, a negative regulator of the immune system. The authors report on advanced …